{"id":1690,"date":"2017-10-26T19:58:54","date_gmt":"2017-10-26T19:58:54","guid":{"rendered":"http:\/\/www.enyopharma.com\/fr\/enyo-pharma-opens-a-new-subsidiary-in-australia-as-a-new-managing-center-for-clinical-trials\/"},"modified":"2018-02-27T12:17:50","modified_gmt":"2018-02-27T12:17:50","slug":"enyo-pharma-opens-a-new-subsidiary-in-australia-as-a-new-managing-center-for-clinical-trials","status":"publish","type":"post","link":"https:\/\/www.enyopharma.com\/fr\/enyo-pharma-opens-a-new-subsidiary-in-australia-as-a-new-managing-center-for-clinical-trials\/","title":{"rendered":"ENYO Pharma ouvre une nouvelle filiale en Australie pour g\u00e9rer ses essais cliniques"},"content":{"rendered":"<p>Lyon, October 26, 2017 &#8211; ENYO Pharma a pris une d\u00e9cision strat\u00e9gique en ouvrant r\u00e9cemment sa premi\u00e8re filiale \u00e0 Melbourne en Australie, du fait de ses excellentes capacit\u00e9s de d\u00e9veloppement d\u2019essais cliniques et des conditions favorables offertes par les autorit\u00e9s locales. En effet, le gouvernement australien apporte un soutien important aux startups de biotechnologie et le bureau d\u2019affaires du gouvernement victorien fournit un bon r\u00e9seau de d\u00e9veloppement commercial et partenarial. Ce nouveau bureau g\u00e9rera les essais cliniques d\u2019EYP001 (un agoniste de FXR) dans la r\u00e9gion Asie-Pacifique sur des patients atteints d\u2019h\u00e9patite B chronique.<\/p>\n <a href=\"http:\/\/www.enyopharma.com\/wp-content\/uploads\/2017\/10\/ENYO-Pharma-PR-Australie-Oct-17-Fran\u00e7ais-Final-version.pdf\" target=\"_blank\" rel=\"\" target=\"_blank\" class=\"tano-file\"><span class=\"tano_download_icon\"><\/span><span class=\"tano_file_title\">T\u00e9l\u00e9charger le communiqu\u00e9 complet (PDF)<\/span><\/a> \n","protected":false},"excerpt":{"rendered":"<p>Lyon, October 26, 2017 &#8211; ENYO Pharma a pris une d\u00e9cision strat\u00e9gique en ouvrant r\u00e9cemment sa premi\u00e8re filiale \u00e0 Melbourne en Australie, du fait de ses excellentes capacit\u00e9s de d\u00e9veloppement d\u2019essais cliniques et des conditions favorables offertes par les autorit\u00e9s locales. En effet, le gouvernement australien apporte un soutien important aux startups de biotechnologie et le bureau d\u2019affaires du gouvernement victorien fournit un bon r\u00e9seau de d\u00e9veloppement commercial et partenarial. Ce nouveau bureau g\u00e9rera les essais cliniques d\u2019EYP001 (un agoniste de FXR) dans la r\u00e9gion Asie-Pacifique sur des patients atteints d\u2019h\u00e9patite B chronique.<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/www.enyopharma.com\/fr\/enyo-pharma-opens-a-new-subsidiary-in-australia-as-a-new-managing-center-for-clinical-trials\/\">Lire la suite&nbsp;&raquo;<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[17],"tags":[31,32,33,34,35],"class_list":["post-1690","post","type-post","status-publish","format-standard","hentry","category-press-releases-fr","tag-australia-fr","tag-clinical-trials-fr","tag-managing-center-fr","tag-new-fr","tag-subsidiary-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"editorENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/editorenyopharma\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.enyopharma.com\/fr\/category\/press-releases-fr\/\" rel=\"category tag\">Press releases<\/a>","rttpg_excerpt":"Lyon, October 26, 2017 &#8211; ENYO Pharma a pris une d\u00e9cision strat\u00e9gique en ouvrant r\u00e9cemment sa premi\u00e8re filiale \u00e0 Melbourne en Australie, du fait de ses excellentes capacit\u00e9s de d\u00e9veloppement d\u2019essais cliniques et des conditions favorables offertes par les autorit\u00e9s locales. En effet, le gouvernement australien apporte un soutien important aux startups de biotechnologie et&hellip;","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/1690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=1690"}],"version-history":[{"count":7,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/1690\/revisions"}],"predecessor-version":[{"id":1884,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/1690\/revisions\/1884"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=1690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=1690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=1690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}